Inhaled aerosolized prostacyclin (IAP) is used as a selective pulmonary vasodilator (SPV) in the treatment of severe hypoxaemia and pulmonary hypertension, as may occur in the acute respiratory distress syndrome (ARDS) [1] [2] [3] [4] . Since the first descriptions of IAP therapy 5, 6 , there has been an awareness of the potential for inhaled prostacyclin to reach the systemic circulation.
Prostacyclin rapidly hydrolyses to 6-ketoprostaglandin F 1 α. Both prostacyclin and its major metabolite, 6-keto-prostaglandin F 1 α, are potent inhibitors of platelet aggregation, acting via cyclic adenosine monophosphate (cAMP) 6 . A recent report indicated that systemic plasma levels of 6-ketoprostaglandin F 1 α during IAP therapy, measured by radio-immunoassay (RIA), were greater than 600 pg/ml 7 .
The aim of the current study was to determine whether low concentrations of prostacyclin, as may be encountered during IAP therapy, affect platelet function in vitro as measured by a reduction in platelet aggregation responses to adenosine diphosphate (ADP) and collagen. Thromboelastography (TEG) was used as an additional measure of platelet function.
METHOD
Institutional ethics committee approval and written informed consent was obtained prior to recruiting eight healthy adult volunteers (four male and four female, aged 28 to 46 years) to participate in the study. None of the volunteers was taking medication known to affect platelet function. Venous blood was drawn from each volunteer for testing as follows.
Blood Samples
Blood samples were obtained from an antecubital vein with a 21 gauge winged infusion set (Surflo, Terumo Medical Corp., Elkton, MD, U.S.A.) into a vacuum tube blood collection system (Vacutainer™). Each sample was collected into a siliconized glass tube containing 1 part 3.8% sodium citrate per 9 parts blood. Blood for the TEG was collected in a plastic syringe prior to testing in the TEG. 
SUMMARY
The study was performed to determine the possible direct effects of low concentrations of prostacyclin that might spill over into the systemic circulation during the administration of inhaled aerosolized prostacyclin.
Platelet aggregation in response to adenosine diphosphate and collagen, as well as measurement of the maximum amplitude of the thrombelastograph (TEG), was undertaken in vitro using venous blood exposed to low concentrations of prostacyclin (0, 10, 100 and 500 pg/ml) from eight healthy volunteers.
There were statistically significant reductions in parameters of platelet aggregation in response to the agonists adenosine diphosphate (1 µmol/l and 8 µmol/l) and collagen (10 µmol/l) following exposure to as little as 10 pg/ml of prostacyclin. The maximum amplitude of the TEG was unchanged over the entire range of prostacyclin concentrations studied.
The results indicate that low concentrations of prostacyclin or prostacyclin metabolite such as may be observed during inhaled aerosolized prostacyclin therapy are likely to be associated with a marked platelet aggregation defect. This defect was not detected by the TEG.
Platelet Aggregation Studies
Prostacyclin (epoprostenol, Flolan, Glaxo-Wellcome, Boronia, Victoria, Australia) in a 100 µl volume was added immediately to each 5 ml blood sample, collected as above, using a micro-pipette to produce final prostacyclin concentrations of 10 pg/ml, 100 pg/ml or 500 pg/ml. A control sample, to which 100 µl of normal saline was added, was included for each volunteer.
Platelet aggregation studies were carried out on these samples within 10 minutes. The samples were centrifuged at 150 G for 15 minutes to produce platelet rich plasma (PRP) and at 1500 G for 20 minutes to obtain platelet poor plasma (PPP). The PRP was diluted with PPP to a final platelet count of approximately 250 2 10 -9 /l. Platelet aggregation was performed using a Daiichi Monitor IV aggregation recorder (Helena Laboratories, Beaumont, Texas, U.S.A.). Platelet aggregation was induced with adenosine diphosphate (ADP) sodium salt in Owrens buffer (Sigma Chemicals, St Louis, U.S.A.) in final concentrations of 1 µmol/l and 8 µmol/l. Reagent Horm collagen (Paxton Scientific Pty Ltd, Victor Harbour, Australia) in a final concentration of 10 µmol/l was also used to induce aggregation. The maximal rate of aggregation (slope) and the extent of aggregation (maximal and after four minutes) were determined.
Thrombelastography (TEG)
Two computerized TEG machines were used, providing four channels simultaneously. Calibration of the maximum amplitude (MA) was checked using calibration pins (Haemoscope Corp., Skokie, IL, U.S.A.). Venous blood (0.35 ml) was added to disposable plastic cups in each channel. Prostacyclin was then added in a 10 µl volume using a micro-pipette to produce final prostacyclin concentrations in each of the cups of 10 pg/ml, 100 pg/ml or 500 pg/ml. A control sample (10 µl of normal saline) was used for each volunteer. The order of the TEG channels used for each prostacyclin concentration was randomized for each volunteer. The reaction time (R), coagulation time (K) and the maximum amplitude (MA) of each TEG run were recorded.
Statistics
Statistical analysis included comparison of the baseline and treatment groups, for maximal rate of aggregation and extent of aggregation (maximum and after four minutes), by means of Wilcoxon signed rank tests. The Wilcoxon signed rank test was also used to compare the MA of the TEG at the various concentrations of prostacyclin to control values. P values <0.05 were deemed statistically significant.
RESULTS

Platelet Aggregation Studies
There was a significant reduction in maximum platelet aggregation response to both 1 µmol/l and 8 µmol/l ADP at prostacyclin concentrations of 10 pg/ml, 100 pg/ml and 500 pg/ml. The maximum platelet aggregation response to collagen was significantly impaired only at the 100 pg/ml and 500 pg/ml concentrations of prostacyclin. These results are shown in Figure 1 .
Platelet aggregation at four minutes in response to ADP (1 µmol/l and 8 µmol/l) and collagen (10 µmol/l) was significantly reduced at the 100 pg/ml and 500 pg/ml prostacyclin concentrations, but not at the 10 pg/ml prostacyclin concentration.
The rate of aggregation to ADP 1 µmol/l was significantly decreased at all the prostacyclin concentrations tested. The rate of aggregation in response to ADP (8 µmol/l) or collagen (10 µmol/l) was significantly reduced at the 100 pg/ml and 500 pg/ml prostacyclin concentrations, but not at the 10 pg/ml level. The rates of aggregation in response to challenge with ADP (1 µmol/l and 8 µmol/l) and collagen (10 µmol/l) are shown in Table 1 .
TEG
The maximum amplitudes (MA) obtained at baseline and at each of the three concentrations of prostacyclin are shown in Table 2 . There were no statistical differences between the MAs at the various concentrations compared to baseline. The mean R and K times for each concentration of prostacyclin remained within normal limits. 344 P. V. VAN 
DISCUSSION
This study demonstrates a significant platelet aggregation defect in vitro at levels of prostacyclin as low as 10 pg/ml. Very low systemic plasma levels of prostacyclin and 6-keto-prostaglandin F 1 α may therefore be associated with a platelet aggregation defect. This defect, which may develop during IAP therapy, is detected by abnormal platelet aggregation studies, but not by TEG.
Platelet aggregation responses to agonists such as ADP and collagen are a sensitive method of assessing platelet inhibition by antiplatelet drugs 8 . The concentration of agonists required to induce aggregation is a measure of the potency of the inhibition. The finding of dose-related inhibition of platelet aggregation to high concentrations of ADP and collagen indicate that prostacyclin is a potent inhibitor of platelet aggregation, even at the low levels that may occur during IAP therapy.
However, platelet aggregation responses do not assess the contribution of other coagulation elements that occur in vivo. Thromboelastography provides a dynamic assessment of clot formation in whole blood and has proved useful as a point of care monitor of coagulation 9 . The MA of the TEG is a measure of the maximum strength of clot, which is dependent on the interaction between fibrinogen and platelets 9 . A platelet defect should manifest as a reduction in MA 9 . However, because the TEG uses whole blood, thrombin is generated which is a potent activator of platelet aggregation and which acts through a different pathway to prostacyclin 10 . As no reduction in MA was observed, this may indicate the generation of thrombin in the TEG cup. In any event, the results indicate that platelet aggregation studies rather than TEG should be used for monitoring platelet function during IAP therapy or other situations where low levels of prostacyclin are encountered.
Inhaled aerosolized prostacyclin has been shown to be a potent selective pulmonary vasodilator [1] [2] [3] [4] . Its use in reducing pulmonary arterial pressure and improving oxygenation has been demonstrated adequately in patients with acute lung injury 2, 4 . However, the toxicity of IAP has not been well elucidated. One area of concern with regard to toxicity of this therapy is the known potent anti-platelet effects of both prostacyclin and its metabolite 6-keto-prostaglandin F 1 α.
A separate report 7 describes levels of 6-ketoprostaglandin F 1 α of over 600 pg/ml in the plasma of a patient with ARDS being treated with IAP at doses of not more than 50 ng/kg/min (i.e. the currently accepted therapeutic range). The premise of the current study is that these levels of 6-keto-prostaglandin F 1 α encountered in the systemic circulation during IAP therapy are responsible for a significant platelet aggregation defect.
An assumption drawn in the conduct of this study is that although plasma levels of 6-keto-prostaglandin F 1 α are reported during IAP therapy, due to the ephemeral nature of prostacyclin, the platelet aggregation defect seen in vivo would be a result of the action on platelets, via cAMP, of both prostacyclin and 6-keto-prostaglandin F 1 α. So, although prostacyclin was added to the test tube in this study, rapid hydrolysis of the prostacyclin to 6-keto-prostaglandin F 1 α would result in an anti-platelet effect due to both the parent compound and the metabolite, much as would occur in vivo. It is not possible however to equate with absolute certainty the levels of 6-ketoprostaglandin F 1 α in the patient reported 7 and the amount of prostacyclin added in vitro in this study. However, the report 7 also demonstrates a platelet aggregation defect in response to ADP in association with the raised plasma levels of 6-keto-prostaglandin F 1 α. 
CONCLUSION
Low concentrations of prostacyclin, as may be seen in the systemic circulation during IAP therapy, have potent antiplatelet effects as determined by platelet aggregation studies. The TEG does not appear to be sufficiently sensitive to detect these changes. This study suggests that platelet aggregation studies and not TEG should be used for monitoring of platelet function when IAP is administered.
